GNFTF.US Genfit SA

Healthcare Biotechnology USA Stocks
9.43 USD
Close of Nov 14, 2026
4.55 16.50
Market cap
USD 472M
P/E
-
P/B
3.02x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is GNFTF.US undervalued?

Graham number

The Graham number of Genfit SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genfit SA fundamental analysis

No fundamental analysis for Genfit SA yet.

Genfit SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genfit SA

Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, w…

Full company profile